Stay updated on Ipilimumab Nivolumab Combo in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab Nivolumab Combo in Melanoma Clinical Trial page.

Latest updates to the Ipilimumab Nivolumab Combo in Melanoma Clinical Trial page
- Check3 days agoChange DetectedAdded Melanoma label and related topics (MedlinePlus Genetics). Site revision updated to v3.5.0, replacing v3.4.3.SummaryDifference0.2%

- Check10 days agoChange DetectedRevision: v3.4.3 added and v3.4.2 removed.SummaryDifference0.1%

- Check17 days agoChange DetectedThe study page no longer lists Melanoma as the primary condition, and the 'MedlinePlus Genetics' related topics section has been removed.SummaryDifference0.2%

- Check24 days agoNo Change Detected
- Check39 days agoChange DetectedAdded Revision: v3.4.2; removed the government funding operating-status banner. Core study content, including eligibility criteria, interventions, and outcomes, remains unchanged.SummaryDifference0.4%

- Check46 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and current operating status. Updated the page revision to v3.4.1, replacing v3.4.0.SummaryDifference0.4%

- Check53 days agoChange DetectedUI/metadata updates include adding glossary display, melanoma as a related topic, MedlinePlus Genetics, and a new revision tag (v3.4.0), replacing older QC-related labels. The old labels Last Update Submitted that met QC Criteria, No FEAR Act data, and v3.3.4 were removed.SummaryDifference0.4%

Stay in the know with updates to Ipilimumab Nivolumab Combo in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab Nivolumab Combo in Melanoma Clinical Trial page.